Overture Life has received regulatory clearance for its DaVitri automated fertility preservation platform in Brazil, expanding the technology’s availability in Latin America, the company announced today.
Brazil’s National Health Surveillance Agency (ANVISA) has cleared the DaVitri platform for commercial use as a class I medical device, making Brazil the sixth country in South and Central America where the technology can be used to automate vitrification in IVF procedures.
The platform is designed to standardize the vitrification process, aiming to improve quality and consistency while reducing the number of IVF cycles required. According to the company, the DaVitri technology has already been deployed in Panama, Chile, Dominican Republic, Argentina, and recently in Peru.
“We thank the regulators at ANVISA for their thorough review of DaVitri’s technical, performance, and safety data,” said Hans Gangeskar, CEO of Overture Life. “ANVISA’s reputation for stringent review not only offers assurance to those in Brazil seeking to utilize IVF, but further supports our belief that widespread use of the automated DaVitri device will usher in a new era for quality, accessible reproductive healthcare.”
The tabletop DaVitri system is part of Overture’s mission to modernize IVF by incorporating AI, automation, metabolomics, and microfluidics into fertility treatments. The company states that this approach could eventually enable vitrification at specialist offices, potentially making IVF more accessible globally.
“We have been using the DaVitri system since June 2024 to automate vitrification. It increases our efficiency and makes our work more reproducible and safer for patients and physicians,” said Dr. Jorge Castillo Baso, a specialist in gynecology and obstetrics and a founding partner of Ferticlinic and Fertidonors in Panama. “It improves the consistency of results and eliminates variability caused by human intervention, where errors can occur. It also frees up our embryologists’ workload, allowing Ferticlinic to perform more procedures without compromising quality.”
Overture Life, which maintains research and development operations in Spain and clinical operations in the United States, including a CLIA-licensed laboratory for non-invasive embryo selection, is backed by investors including Overwater Ventures, GV (formerly Google Ventures), Khosla Ventures, and Octopus Ventures.
